Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

WIIM

Coya Therapeutics shares are trading higher after the company announced it will report results from an investigator-initiated Phase 2 trial of low-dose interleukin-2 in patients with mild-to-moderate Alzheimer's disease. - Coya Therapeutics (NASDAQ:COYA)

Benzinga Newsdesk

Coya Therapeutics

COYA

Coya Therapeutics shares are trading higher after the company announced it will report results from an investigator-initiated Phase 2 trial of low-dose interleukin-2 in patients with mild-to-moderate Alzheimer's disease.

Comments